
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem Inc. has demonstrated promising early efficacy with its drug combination of avutometinib and defactinib, particularly in low-grade serous ovarian carcinoma (LGSOC), which may establish a new standard of care for approximately 1,000 to 2,000 new patients annually. The company reported an overall response rate (ORR) of 68.8% and a disease control rate (DCR) of 93.8% in non-small cell lung cancer (NSCLC) patients treated at the recommended Phase 2 dose, indicating strong overall therapeutic potential. Additionally, the anticipated enhancement of tolerability through improved dosing strategies and supportive care measures further supports a positive outlook on Verastem's pipeline and potential market position.
Bears say
Verastem Inc. faces a negative outlook due to the observed lower overall response rates (ORR) in its treatment candidate for KRAS G12D mutations, compared to competitive therapies, indicating potential efficacy challenges in key cancer markets such as pancreatic cancer and non-small cell lung cancer (NSCLC). Additionally, the recent protocol changes in Phase 3 trials, which allow for dose reductions due to high-grade CPK elevations, could lead to even poorer patient prognoses and lower response rates than previously encountered in other KRAS mutation contexts. Furthermore, the toxicity issues associated with MEK inhibitors may result in significant patient dropouts during studies, further undermining the potential for successful outcomes in Verastem's developmental pipeline.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares